DekaBank Deutsche Girozentrale
BLCM

DekaBank Deutsche Girozentrale’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,400
Closed -$123K – 1060
2016
Q1 		$123K Buy
+1,400
New +$152K ﹤0.01% 930

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DekaBank Deutsche Girozentrale's BLCM Position: Q2 2016 in Review

DekaBank Deutsche Girozentrale sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2016, closing a stake of 1,400 shares — an estimated $123K sold.

DekaBank Deutsche Girozentrale first reported a position in BLCM in Q1 2016 and held it in 1 quarter. The position peaked at $123K in Q1 2016. 67 funds tracked by Wall St. Rank hold BLCM as of Q2 2016.

  • DekaBank Deutsche Girozentrale reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 1,400 Bellicum Pharmaceuticals, Inc. shares in Q2 2016, an estimated $123K.
  • DekaBank Deutsche Girozentrale first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
  • DekaBank Deutsche Girozentrale's Bellicum Pharmaceuticals, Inc. position peaked at $123K in Q1 2016.
  • 67 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2016.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2016, filed 4 Aug 2016.